The AJMC® clinical page includes all the published content across AJMC.com, The American Journal of Managed Care® and Evidence-Based Oncology™ on a variety of specialties, including dermatology, cardiology, oncology, and rheumatology.
April 18th 2025
From Crohn disease to uncomplicated urinary tract infections and beyond, the FDA issued several high-impact drug approvals last month.
Liquid Biopsy Might Be Useful in the Detection of Colorectal, Lung Cancer
September 6th 2023Investigators wanted to analyze the diagnostic performance of methylation-sensitive restriction enzyme digestion followed by sequencing using cell-free DNA and explore the cancer signal origin of the cancer using DNN analyses for colorectal and lung cancers.
Read More
Evidence Insufficient to Show That Probiotics Prevent CDI
September 5th 2023Although 3 of 7 studies analyzed demonstrated that using probiotics could help prevent the development of Clostridioides difficile infection (CDI) in older patients, the researchers did not find a consensus among them all.
Read More
Postoperative ctDNA Provides Prognostic Value for DFS Outcomes in CRC
September 4th 2023Circulating tumor DNA (ctDNA) status at the time of postoperative minimal residual disease assessment is a prognostic factor for disease-free survival (DFS) in patients with radically resected stage II to IV colorectal cancer (CRC).
Read More
Cost Analysis of Self-Monitoring Blood Glucose in Nonintensively Managed Type 2 Diabetes
Analysis of claims data showed reduced utilization and costs among patients with nonintensively managed type 2 diabetes using self-monitoring of blood glucose compared with continuous glucose monitoring.
Read More
HER2 Amplification Shows Prognostic Capabilities in mCRC
August 28th 2023Although HER2 amplification showed prognostic capabilities in patients with RAS wild-type metastatic colorectal cancer (mCRC), it was not predictive of survival benefit as a first-line treatment option in combination with panitumumab vs standard-of-care bevacizumab.
Read More
Study Suggests CAR T-Cell Therapy Safe, Effective After Allo-SCT in Multiple Myeloma
August 26th 2023A retrospective analysis of the CARTITUDE-1 trial suggests that patients who have undergone allogeneic stem cell transplant (allo-SCT) prior to receiving chimeric antigen receptor (CAR) T-cell therapy for multiple myeloma experience comparable outcomes to allo-SCT–naïve patients.
Read More